Interdisciplinary GU Cancer Forum 2025, Prostate Cancer, Neoadjuvant Management of High-Risk Prostate Cancer, PROTEUS trial, GUNS trial, Genomic Umbrella Neoadjuvant Study, apalutamide, FOXA1 alterations, Lutectomy trial, 177Lu-PSMA-617, LuPSMA, TMPRSS2-ERG fusions, Lutectomy trial.
SNMMI 2025 STARLiT trial, stereotactic body radiotherapy (SBRT) plus 177Lu PSMA-617 in patients with locally advanced prostate cancer, ADT +/- abiraterone/prednisone.
International guidelines recommend salvage radiotherapy (sRT) as a curative treatment for men with biochemically recurrent prostate cancer after radical prostatectomy. Prostate-specific membrane antigen (PSMA) PET/CT…
Zachary Klaassen interviews Neal Shore about real-world treatment patterns for mCRPC patients in community urology centers using the PRECISION database. Dr. Shore analyzes data from…
SNMMI 2025, Prostate Cancer, Radioimmunotherapy Agent, CD46-Targeted Antibody-Drug Conjugate, CD46-Targeted Antibody-Drug Conjugate and a Radioimmunotherapy Agent for the Treatment of Prostate Cancer, anti-CD46 targeted antibody,…
Interdisciplinary GU Cancer Forum 2025, Metastatic Urothelial Carcinoma, enfortumab vedotin, Nectin-4 antibody drug conjugate, CRB-701, BT8009-100, DURAVELO-1 trial, DURAVELO-2 trial, zelenectide pevedotin, pembrolizumab, zelenectide pevedotin…
Interdisciplinary GU Cancer Forum 2025, urothelial carcinoma, Metastatic Urothelial Carcinoma, enfortumab vedotin, advanced urothelial carcinoma when enfortumab vedotin, Optimal Sequence of Treatment for Metastatic Urothelial…
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in monitoring patients with metastatic disease, tumor-derived DNA, KEYNOTE-361 trial.
Interdisciplinary GU Cancer Forum 2025, role of ctDNA in selecting adjuvant therapy post-cystectomy, pelvic lymph node dissection for invasive bladder cancer.
urothelial carcinoma, muscle invasive bladder cancer (MIBC), NIAGARA trial, perioperative immune checkpoint inhibitor, durvalumab, enfortumab vedotin, KEYNOTE-905/EV-303 trial, VOLGA trial.
non muscle invasive bladder cancer (NMIBC), Bacillus Calmette-Guérin (BCG) therapy, BCG unresponsive disease.
